These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 36200687)

  • 1. Cisplatin-induced HSF1-HSP90 axis enhances the expression of functional PD-L1 in oral squamous cell carcinoma.
    Sasaya T; Kubo T; Murata K; Mizue Y; Sasaki K; Yanagawa J; Imagawa M; Kato H; Tsukahara T; Kanaseki T; Tamura Y; Miyazaki A; Hirohashi Y; Torigoe T
    Cancer Med; 2023 Feb; 12(4):4605-4615. PubMed ID: 36200687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expression.
    Zhang Z; Sun D; Tang H; Ren J; Yin S; Yang K
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37914384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bromodomain-containing protein 4 inhibition improves the efficacy of cisplatin and radiotherapy in oral squamous cell carcinoma by suppressing programmed cell death-ligand 1 expression.
    Ren J
    Basic Clin Pharmacol Toxicol; 2024 Feb; 134(2):272-283. PubMed ID: 38014458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
    Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
    Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin-induced programmed cell death ligand-2 expression is associated with metastasis ability in oral squamous cell carcinoma.
    Sudo S; Kajiya H; Okano S; Sasaki M; Katsumata Y; Ohno J; Ikebe T; Hiraki A; Okabe K
    Cancer Sci; 2020 Apr; 111(4):1113-1123. PubMed ID: 32012401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triptolide suppresses oral cancer cell PD-L1 expression in the interferon-γ-modulated microenvironment in vitro, in vivo, and in clinical patients.
    Kuo CS; Yang CY; Lin CK; Lin GJ; Sytwu HK; Chen YW
    Biomed Pharmacother; 2021 Jan; 133():111057. PubMed ID: 33378962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1-Mediated Immunosuppression in Oral Squamous Cell Carcinoma: Relationship With Macrophage Infiltration and Epithelial to Mesenchymal Transition Markers.
    Wu T; Tang C; Tao R; Yong X; Jiang Q; Feng C
    Front Immunol; 2021; 12():693881. PubMed ID: 34552581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a Favorable Prognostic Subgroup in Oral Squamous Cell Carcinoma: Characterization of ITGB4/PD-L1
    Ma SR; Liu JF; Jia R; Deng WW; Jia J
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Immune Checkpoint BTLA in Oral Cancer: Expression Analysis and Its Correlation to Other Immune Modulators.
    Ries J; Trumet L; Hahn A; Kunater L; Lutz R; Geppert C; Kesting M; Weber M
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TLR9 activation induces immunosuppression and tumorigenesis via PARP1/PD-L1 signaling pathway in oral squamous cell carcinoma.
    Ma L; Qin N; Wan W; Song S; Hua S; Jiang C; Li N; Huang L; Gao X
    Am J Physiol Cell Physiol; 2024 Feb; 326(2):C362-C381. PubMed ID: 38105756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-inhibition of adenosine 2b receptor and programmed death-ligand 1 promotes the recruitment and cytotoxicity of natural killer cells in oral squamous cell carcinoma.
    Wang B; Wang T; Yang C; Nan Z; Ai D; Wang X; Wang H; Qu X; Wei F
    PeerJ; 2023; 11():e15922. PubMed ID: 37663280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside.
    Nocini R; Vianini M; Girolami I; Calabrese L; Scarpa A; Martini M; Morbini P; Marletta S; Brunelli M; Molteni G; Parwani A; Pantanowitz L; Eccher A
    Clin Exp Dent Res; 2022 Jun; 8(3):690-698. PubMed ID: 35593124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.
    Quan H; Liu S; Shan Z; Liu Z; Chen T; Hu Y; Yao Z; Fang L
    Arch Oral Biol; 2020 Nov; 119():104916. PubMed ID: 32977151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Situ PD-L1 Expression in Oral Squamous Cell Carcinoma Is Induced by Heterogeneous Mechanisms among Patients.
    Kondo Y; Suzuki S; Ono S; Goto M; Miyabe S; Ogawa T; Tsuchida H; Ito H; Takahara T; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors.
    Gao A; Pan X; Yang X; Lin Z
    Invest New Drugs; 2021 Aug; 39(4):1132-1138. PubMed ID: 33594603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CMTM6 attenuates cisplatin-induced cell death in OSCC by regulating AKT/c-Myc-driven ribosome biogenesis.
    Mohapatra P; Mohanty S; Ansari SA; Shriwas O; Ghosh A; Rath R; Majumdar SKD; Swain RK; Raghav SK; Dash R
    FASEB J; 2022 Oct; 36(10):e22566. PubMed ID: 36165231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-132 inhibits migration and invasion and increases chemosensitivity of cisplatin-resistant oral squamous cell carcinoma cells via targeting TGF-β1.
    Chen L; Zhu Q; Lu L; Liu Y
    Bioengineered; 2020 Dec; 11(1):91-102. PubMed ID: 31906769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Candida albicans induces upregulation of programmed death ligand 1 in oral squamous cell carcinoma.
    Wang X; Zhao W; Zhang W; Wu S; Yan Z
    J Oral Pathol Med; 2022 May; 51(5):444-453. PubMed ID: 35362187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AIM2 promotes irradiation resistance, migration ability and PD-L1 expression through STAT1/NF-κB activation in oral squamous cell carcinoma.
    Chiu HW; Lee HL; Lee HH; Lu HW; Lin KY; Lin YF; Lin CH
    J Transl Med; 2024 Jan; 22(1):13. PubMed ID: 38166970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.